Gossamer Bio, Inc. (GOSS)
NASDAQ: GOSS · Real-Time Price · USD
0.3449
-0.0036 (-1.03%)
At close: Apr 28, 2026, 4:00 PM EDT
0.3420
-0.0029 (-0.84%)
After-hours: Apr 28, 2026, 7:22 PM EDT
Gossamer Bio Stock Forecast
GOSS's stock price has decreased by -64.01% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 7 analysts that cover Gossamer Bio stock have a consensus rating of "Buy" and an average price target of $4.19, which forecasts a 1,114.84% increase in the stock price over the next year. The lowest target is $0.30 and the highest is $11.
Price Target: $4.19 (+1,114.84%)
Analyst Consensus: Buy
* Price targets were last updated on Mar 6, 2026.
Analyst Ratings
The average analyst rating for Gossamer Bio stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 2 | 2 |
| Buy | 3 | 3 | 4 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 2 | 3 | 3 |
| Sell | 0 | 0 | 0 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 7 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Mar 23, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 → $5 | Strong Buy | Maintains | $10 → $5 | +1,349.70% | Mar 6, 2026 |
| Oppenheimer | Oppenheimer | Buy Maintains $12 → $3 | Buy | Maintains | $12 → $3 | +769.82% | Mar 5, 2026 |
| Wedbush | Wedbush | Buy → Hold Downgrades $6 → $1 | Buy → Hold | Downgrades | $6 → $1 | +189.94% | Feb 24, 2026 |
| Barclays | Barclays | Buy → Sell Downgrades $9 → $0.3 | Buy → Sell | Downgrades | $9 → $0.3 | -13.02% | Feb 24, 2026 |
Financial Forecast
Revenue This Year
20.54M
from 48.47M
Decreased by -57.63%
Revenue Next Year
61.94M
from 20.54M
Increased by 201.64%
EPS This Year
-0.49
from -0.75
EPS Next Year
-0.19
from -0.49
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 39.6M | 117.9M | ||||||
| Avg | 20.5M | 61.9M | ||||||
| Low | n/a | 19.4M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -18.2% | 473.9% | ||||||
| Avg | -57.6% | 201.6% | ||||||
| Low | - | -5.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.21 | -0.02 | ||||||
| Avg | -0.49 | -0.19 | ||||||
| Low | -0.77 | -0.42 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.